Lantus (insulin glargine) / Sanofi 
Welcome,         Profile    Billing    Logout  
 89 Diseases   30 Trials   30 Trials   3067 News 


12345678910111213...2829»
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    SGLTI-INDUCED EDKA: A COMMON ADVERSE REACTION WITH AN UNPREDICTABLE COURSE (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7013;    
    Although this patient had a favorable outcome, it is important to document cases as SGLT2 inhibitors become guideline therapy for various mainstem treatments. With the understanding of the side effect, it can lead to better patient management and expectations when treating this condition.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    MYOPATHY LEADING TO RHABDOMYOLYSIS AS A RARE SIDE EFFECT OF LENVATINIB AND PEMBROLUZIMAB THERAPY (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_5900;    
    Myositis and rhabdomyolysis have also been reported in the literature as a rare side effect in anti-PDL-1 drugs, such as pembrolizumab, and anti-CTLA-4 drugs, such as ipilimumab.[3,4] One proposed mechanism to this process is new autoimmune hypothyroidism leading to rhabdomyolysis.[5] In patients who are on both TKI's and ICI's, it may be difficult to discern the instigating agent as illustrated in this case report...Prior to admission, she was taking amlodipine, diazepam, glipizide, Lantus, levothyroxine, lisinopril-hydrochlorothiazide, metformin, rosuvastatin, pembrolizumab, and lenvatinib for several months... Serial CK levels can be useful in patients presenting to the clinic with muscle pain or weakness.7 Routine screening for musculoskeletal symptoms in patients on TKI's and ICI's should be a part of regular follow up.
  • ||||||||||  Preclinical, Journal:  Assessment of subcutaneously administered insulins using in vitro release cartridge: Medium composition and albumin binding. (Pubmed Central) -  Jul 31, 2024   
    Albumin-binding acylated insulin analogs exhibited rapid disappearance from the cartridge; however, sustained retention was achieved by coupling albumin to the matrix. An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions.
  • ||||||||||  LVAD Patient Presenting for Urgent Laparoscopic Surgery: What Do I Do? (126A) -  Jun 25, 2024 - Abstract #ASA2024ASA_1854;    
    An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions. Abstract is embargoed at this time.
  • ||||||||||  Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi
    Safety and Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus (T2DM) in South Korea (Poster Hall (West A4-B2); 811) -  May 20, 2024 - Abstract #ADA2024ADA_2844;    
    GL Glargine demonstrated similar immunogenicity, efficacy, and safety compared to Lantus In clinical practice, iGlarLixi has shown to be safe and well tolerated without new safety concerns improving clinical outcomes in people with T2DM in South Korea.
  • ||||||||||  Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi
    Insulin Therapy Deintensification with iGlarLixi (Poster Hall (West A4-B2); 782) -  May 20, 2024 - Abstract #ADA2024ADA_2812;    
    In clinical practice, iGlarLixi has shown to be safe and well tolerated without new safety concerns improving clinical outcomes in people with T2DM in South Korea. Insulin therapy de-intensification from MDI into iGlarLixi is an efficient and safe treatment option for PwT2D that provides comparable glycemic control with the benefits of reduction of BW, TDD, number of insulin injections and lower proportion of visits as which hypoglycemia was reported.
  • ||||||||||  Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi
    Soli-SWITCH (Poster Hall (West A4-B2); 780) -  May 20, 2024 - Abstract #ADA2024ADA_2810;    
    P4
    These data suggest that iGlarLixi may be a potentially simplified treatment alternative for people with T2D currently receiving two daily injections of PIs. Switching from PI to iGlarLixi offered a simplified treatment option, with improved glycemic outcomes in people with T2D, with added weight benefits and low hypoglycemia risk.
  • ||||||||||  Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi
    Efficacy and Safety of Switching to iGlarLixi from Premixed Insulin (PI) in South Korean People Living with Type 2 Diabetes (T2D) (Poster Hall (West A4-B2); 765) -  May 20, 2024 - Abstract #ADA2024ADA_2794;    
    P4
    Switching from PI to iGlarLixi offered a simplified treatment option, with improved glycemic outcomes in people with T2D, with added weight benefits and low hypoglycemia risk. In this sub-analysis of Soli-SWITCH, iGlarLixi demonstrated improved glycemic outcomes in South Korean participants living with T2D switching from PI, and may represent a simplified and efficacious treatment option vs PI in people of Asian ethnicity.
  • ||||||||||  Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi
    A Real-World Study Assessing the Efficacy and Safety of Switching from Basal (Poster Hall (West A4-B2); 1867) -  May 20, 2024 - Abstract #ADA2024ADA_1824;    
    In this 24-week, multicenter, open-label, Phase 3 study, insulin-na In a real-world setting, people with T2D and elevated HbA1c switching from a BBI regimen to a once-daily injection of iGlarLixi achieved lower HbA1c, weight benefit and numerically lower hypoglycemic events.
  • ||||||||||  Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
    Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin (Poster Hall (West A4-B2); 1880) -  May 20, 2024 - Abstract #ADA2024ADA_1528;    
    A systematic review identified recently published randomized controlled trials (RCTs) by searching Embase (including congress abstracts from 2021-2023), MEDLINE, and CENTRAL in October 2023... Treatment with iGlarLixi versus premix IDegAsp was associated with a greater reduction in HbA1c, PPG, and morning and afternoon SMPG, with less weight gain and lower insulin dose.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Enrollment change, Trial withdrawal:  Empagliflozin Effect on Glucose Toxicity (clinicaltrials.gov) -  May 15, 2024   
    P4,  N=0, Withdrawn, 
    Treatment with iGlarLixi versus premix IDegAsp was associated with a greater reduction in HbA1c, PPG, and morning and afternoon SMPG, with less weight gain and lower insulin dose. N=50 --> 0 | Active, not recruiting --> Withdrawn
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    The impact of interchangeability on biosimilar insulin glargine use and spending in Medicaid () -  Apr 9, 2024 - Abstract #AMCP2024AMCP_68;    
    The introduction of an interchangeable biosimilar for insulin glargine helped reverse the declin- ing trend of the biosimilar market share and generated substantial savings for Medicaid programs. However, use of interchangeable biosimilars varied widely across states, suggesting the need for more education and incentives to promote their adoption.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
    Impact of Health Insurance Claims Denials in the United States: The Case of Insulin Glargine () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1765;    
    Claims denials driven by non-clinical preference for certain products, likely save insurance plans money due to lower net prices they receive for these products. However, these savings must be considered relative to the disruption in care, and administrative burden put on patients and health systems.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Enrollment closed, Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Mar 5, 2024   
    P3,  N=319, Active, not recruiting, 
    Based on pharmacokinetic/pharmacodynamic simulations of Basaglar Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024
  • ||||||||||  SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi
    Journal:  Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial. (Pubmed Central) -  Feb 29, 2024   
    SAR341402 insulin aspart (SAR-Asp) is a rapid-acting insulin analog developed as an interchangeable biosimilar to the marketed insulin aspart reference product (NovoLog; NN-Asp)...This report assessed whether multiple switches between SAR-Asp and NN-Asp lead to equivalent safety and efficacy compared with continuous use of NN-Asp in adults with type 1 diabetes (T1D) treated with multiple daily injections, using once-daily insulin glargine U100 (Lantus) as the basal insulin...Alternating doses of SAR-Asp and NN-Asp compared with continuous use of NN-Asp showed similar safety, immunogenicity, and clinical efficacy in adults with T1D. This study supports interchangeability between SAR-Asp and NN-Asp in T1D management.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Journal:  Prescription drug spending by payer: Implications for managed care. (Pubmed Central) -  Feb 5, 2024   
    The findings highlight the significant impact of the top 10 selling prescription drugs on U.S. prescription drug spending. The wide variation in per prescription cost as well as contribution to each payer's prescription drug burden emphasizes how policies targeting top-selling drugs may differentially impact payers as well as how payer-specific policies may differ substantially even for top selling drugs.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Semglee (insulin glargine-yfgn) / PiSA Farmaceutica, Biocon, Viatris, Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis (clinicaltrials.gov) -  Jan 24, 2024   
    P2,  N=8, Terminated, 
    The wide variation in per prescription cost as well as contribution to each payer's prescription drug burden emphasizes how policies targeting top-selling drugs may differentially impact payers as well as how payer-specific policies may differ substantially even for top selling drugs. N=150 --> 8 | Trial completion date: Feb 2024 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Feb 2023; Study intervention was adopted as standard of care.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Jan 5, 2024   
    P3,  N=264, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Apr 2024 --> Apr 2025
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Dec 26, 2023   
    P3,  N=139, Completed, 
    Trial completion date: Apr 2024 --> Apr 2025 Recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Trial termination:  Insulin Glargine Versus Twice-Daily NPH (clinicaltrials.gov) -  Nov 2, 2023   
    P4,  N=27, Terminated, 
    Budgetary reductions were achieved by switching patients from long-acting BIs to Gla-300. Completed --> Terminated
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Trial completion, Trial completion date:  SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H) (clinicaltrials.gov) -  Sep 25, 2023   
    P4,  N=76, Completed, 
    Completed --> Terminated Recruiting --> Completed | Trial completion date: Jul 2024 --> Aug 2023
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Sep 13, 2023   
    P3,  N=264, Recruiting, 
    Recruiting --> Completed | Trial completion date: Mar 2023 --> Oct 2022 Trial primary completion date: Aug 2023 --> Dec 2023